Forte Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Net Income	-35.48	-31.48	-13.88	-21.71	-46.49	Upgrade
Depreciation & Amortization	0.04	0.01	-	0.04	0.05	Upgrade
Asset Writedown & Restructuring Costs	-	-	-	0.06	30.89	Upgrade
Loss (Gain) From Sale of Investments	-0.16	-0.13	-	-	-	Upgrade
Stock-Based Compensation	3.1	3.28	4.01	4.21	0.96	Upgrade
Change in Accounts Payable	3.02	0.27	0.21	-0.29	-0.37	Upgrade
Change in Other Net Operating Assets	-1.26	-0.66	1.47	1.01	-3.46	Upgrade
Operating Cash Flow	-30.75	-28.71	-8.19	-16.68	-18.42	Upgrade
Capital Expenditures	-0.04	-0.09	-	-	-	Upgrade
Cash Acquisitions	-	-	-	-	3.58	Upgrade
Investment in Securities	-35.96	0.14	-	-	-	Upgrade
Investing Cash Flow	-35.99	0.05	-	-	3.58	Upgrade
Issuance of Common Stock	53.01	25.02	7.24	0.06	66.96	Upgrade
Repurchase of Common Stock	-0.04	-0.06	-	-	-	Upgrade
Other Financing Activities	-1.12	-0.27	-	-0.11	-0.29	Upgrade
Financing Cash Flow	51.86	24.68	7.24	-0.04	66.67	Upgrade
Net Cash Flow	-14.88	-3.98	-0.94	-16.72	51.83	Upgrade
Free Cash Flow	-30.78	-28.79	-8.19	-16.68	-18.42	Upgrade
Free Cash Flow Per Share	-10.56	-22.80	-11.77	-29.85	-62.59	Upgrade
Levered Free Cash Flow	-16.14	-17.4	-3.18	-9.02	-8.1	Upgrade
Unlevered Free Cash Flow	-16.14	-17.4	-3.18	-9.02	-8.1	Upgrade
Change in Net Working Capital	-3.64	0.3	-1.49	-0.16	0.22	Upgrade

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q